Leptin in human physiology and pathophysiology

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Leptin in human physiology and pathophysiology. / Mantzoros, Christos S; Magkos, Faidon; Brinkoetter, Mary; Sienkiewicz, Elizabeth; Dardeno, Tina A; Kim, Sang-Yong; Hamnvik, Ole-Petter R; Koniaris, Anastasia.

I: American Journal of Physiology: Endocrinology and Metabolism, Bind 301, Nr. 4, 2011, s. E567-E584.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Mantzoros, CS, Magkos, F, Brinkoetter, M, Sienkiewicz, E, Dardeno, TA, Kim, S-Y, Hamnvik, O-PR & Koniaris, A 2011, 'Leptin in human physiology and pathophysiology', American Journal of Physiology: Endocrinology and Metabolism, bind 301, nr. 4, s. E567-E584. https://doi.org/10.1152/ajpendo.00315.2011

APA

Mantzoros, C. S., Magkos, F., Brinkoetter, M., Sienkiewicz, E., Dardeno, T. A., Kim, S-Y., Hamnvik, O-P. R., & Koniaris, A. (2011). Leptin in human physiology and pathophysiology. American Journal of Physiology: Endocrinology and Metabolism, 301(4), E567-E584. https://doi.org/10.1152/ajpendo.00315.2011

Vancouver

Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim S-Y o.a. Leptin in human physiology and pathophysiology. American Journal of Physiology: Endocrinology and Metabolism. 2011;301(4):E567-E584. https://doi.org/10.1152/ajpendo.00315.2011

Author

Mantzoros, Christos S ; Magkos, Faidon ; Brinkoetter, Mary ; Sienkiewicz, Elizabeth ; Dardeno, Tina A ; Kim, Sang-Yong ; Hamnvik, Ole-Petter R ; Koniaris, Anastasia. / Leptin in human physiology and pathophysiology. I: American Journal of Physiology: Endocrinology and Metabolism. 2011 ; Bind 301, Nr. 4. s. E567-E584.

Bibtex

@article{868d4c27277e4124ac27607a710ec472,
title = "Leptin in human physiology and pathophysiology",
abstract = "Leptin, discovered through positional cloning 15 years ago, is an adipocyte-secreted hormone with pleiotropic effects in the physiology and pathophysiology of energy homeostasis, endocrinology, and metabolism. Studies in vitro and in animal models highlight the potential for leptin to regulate a number of physiological functions. Available evidence from human studies indicates that leptin has a mainly permissive role, with leptin administration being effective in states of leptin deficiency, less effective in states of leptin adequacy, and largely ineffective in states of leptin excess. Results from interventional studies in humans demonstrate that leptin administration in subjects with congenital complete leptin deficiency or subjects with partial leptin deficiency (subjects with lipoatrophy, congenital or related to HIV infection, and women with hypothalamic amenorrhea) reverses the energy homeostasis and neuroendocrine and metabolic abnormalities associated with these conditions. More specifically, in women with hypothalamic amenorrhea, leptin helps restore abnormalities in hypothalamic-pituitary-peripheral axes including the gonadal, thyroid, growth hormone, and to a lesser extent adrenal axes. Furthermore, leptin results in resumption of menses in the majority of these subjects and, in the long term, may increase bone mineral content and density, especially at the lumbar spine. In patients with congenital or HIV-related lipoatrophy, leptin treatment is also associated with improvements in insulin sensitivity and lipid profile, concomitant with reduced visceral and ectopic fat deposition. In contrast, leptin's effects are largely absent in the obese hyperleptinemic state, probably due to leptin resistance or tolerance. Hence, another emerging area of research pertains to the discovery and/or usefulness of leptin sensitizers. Results from ongoing studies are expected to further increase our understanding of the role of leptin and the potential clinical applications of leptin or its analogs in human therapeutics.",
keywords = "Adipose Tissue/physiology, Amenorrhea/physiopathology, Energy Metabolism/physiology, Female, Homeostasis/physiology, Humans, Hypothalamic Diseases/physiopathology, Hypothalamus/physiology, Leptin/physiology, Male, Neurosecretory Systems/physiology, Reproduction/physiology",
author = "Mantzoros, {Christos S} and Faidon Magkos and Mary Brinkoetter and Elizabeth Sienkiewicz and Dardeno, {Tina A} and Sang-Yong Kim and Hamnvik, {Ole-Petter R} and Anastasia Koniaris",
note = "(Ekstern)",
year = "2011",
doi = "10.1152/ajpendo.00315.2011",
language = "English",
volume = "301",
pages = "E567--E584",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "4",

}

RIS

TY - JOUR

T1 - Leptin in human physiology and pathophysiology

AU - Mantzoros, Christos S

AU - Magkos, Faidon

AU - Brinkoetter, Mary

AU - Sienkiewicz, Elizabeth

AU - Dardeno, Tina A

AU - Kim, Sang-Yong

AU - Hamnvik, Ole-Petter R

AU - Koniaris, Anastasia

N1 - (Ekstern)

PY - 2011

Y1 - 2011

N2 - Leptin, discovered through positional cloning 15 years ago, is an adipocyte-secreted hormone with pleiotropic effects in the physiology and pathophysiology of energy homeostasis, endocrinology, and metabolism. Studies in vitro and in animal models highlight the potential for leptin to regulate a number of physiological functions. Available evidence from human studies indicates that leptin has a mainly permissive role, with leptin administration being effective in states of leptin deficiency, less effective in states of leptin adequacy, and largely ineffective in states of leptin excess. Results from interventional studies in humans demonstrate that leptin administration in subjects with congenital complete leptin deficiency or subjects with partial leptin deficiency (subjects with lipoatrophy, congenital or related to HIV infection, and women with hypothalamic amenorrhea) reverses the energy homeostasis and neuroendocrine and metabolic abnormalities associated with these conditions. More specifically, in women with hypothalamic amenorrhea, leptin helps restore abnormalities in hypothalamic-pituitary-peripheral axes including the gonadal, thyroid, growth hormone, and to a lesser extent adrenal axes. Furthermore, leptin results in resumption of menses in the majority of these subjects and, in the long term, may increase bone mineral content and density, especially at the lumbar spine. In patients with congenital or HIV-related lipoatrophy, leptin treatment is also associated with improvements in insulin sensitivity and lipid profile, concomitant with reduced visceral and ectopic fat deposition. In contrast, leptin's effects are largely absent in the obese hyperleptinemic state, probably due to leptin resistance or tolerance. Hence, another emerging area of research pertains to the discovery and/or usefulness of leptin sensitizers. Results from ongoing studies are expected to further increase our understanding of the role of leptin and the potential clinical applications of leptin or its analogs in human therapeutics.

AB - Leptin, discovered through positional cloning 15 years ago, is an adipocyte-secreted hormone with pleiotropic effects in the physiology and pathophysiology of energy homeostasis, endocrinology, and metabolism. Studies in vitro and in animal models highlight the potential for leptin to regulate a number of physiological functions. Available evidence from human studies indicates that leptin has a mainly permissive role, with leptin administration being effective in states of leptin deficiency, less effective in states of leptin adequacy, and largely ineffective in states of leptin excess. Results from interventional studies in humans demonstrate that leptin administration in subjects with congenital complete leptin deficiency or subjects with partial leptin deficiency (subjects with lipoatrophy, congenital or related to HIV infection, and women with hypothalamic amenorrhea) reverses the energy homeostasis and neuroendocrine and metabolic abnormalities associated with these conditions. More specifically, in women with hypothalamic amenorrhea, leptin helps restore abnormalities in hypothalamic-pituitary-peripheral axes including the gonadal, thyroid, growth hormone, and to a lesser extent adrenal axes. Furthermore, leptin results in resumption of menses in the majority of these subjects and, in the long term, may increase bone mineral content and density, especially at the lumbar spine. In patients with congenital or HIV-related lipoatrophy, leptin treatment is also associated with improvements in insulin sensitivity and lipid profile, concomitant with reduced visceral and ectopic fat deposition. In contrast, leptin's effects are largely absent in the obese hyperleptinemic state, probably due to leptin resistance or tolerance. Hence, another emerging area of research pertains to the discovery and/or usefulness of leptin sensitizers. Results from ongoing studies are expected to further increase our understanding of the role of leptin and the potential clinical applications of leptin or its analogs in human therapeutics.

KW - Adipose Tissue/physiology

KW - Amenorrhea/physiopathology

KW - Energy Metabolism/physiology

KW - Female

KW - Homeostasis/physiology

KW - Humans

KW - Hypothalamic Diseases/physiopathology

KW - Hypothalamus/physiology

KW - Leptin/physiology

KW - Male

KW - Neurosecretory Systems/physiology

KW - Reproduction/physiology

U2 - 10.1152/ajpendo.00315.2011

DO - 10.1152/ajpendo.00315.2011

M3 - Review

C2 - 21791620

VL - 301

SP - E567-E584

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 4

ER -

ID: 290037544